Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Simeon Cua"'
Autor:
Gabriela M. Escalante, Ivana G. Reidel, Lorraine Z. Mutsvunguma, Simeon Cua, Brenda A. Tello, Esther Rodriguez, Mafalda A. Farelo, Cloe Zimmerman, Murali Muniraju, He Li, Aparna N. Govindan, Michael K. Axthelm, Scott W. Wong, Javier Gordon Ogembo
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionEpstein-Barr virus (EBV) is an oncogenic human herpesvirus associated with ~350,000 cases of lymphoid and epithelial malignancies every year, and is etiologically linked to infectious mononucleosis and multiple sclerosis. Despite four dec
Externí odkaz:
https://doaj.org/article/8be24fa2fe95452194f5a54a9cd0960d
Autor:
Simeon Cua, Brenda A. Tello, Mafalda A. Farelo, Esther Rodriguez, Gabriela M. Escalante, Lorraine Z. Mutsvunguma, Javier Gordon Ogembo, Ivana G. Reidel
Publikováno v:
Viruses, Vol 16, Iss 10, p 1628 (2024)
Modified vaccinia Ankara (MVA) virus is a widely used vaccine platform, making accurate titration essential for vaccination studies. However, the current plaque forming unit (PFU) assay, the standard for MVA titration, is prone to observer bias and o
Externí odkaz:
https://doaj.org/article/6122bdc2bc06403c85a43d455514d09e
Publikováno v:
Biotechnology and Bioengineering
This study describes the use of a previously reported chimerised monoclonal antibody (mAb), ch2448, to kill human embryonic stem cells (hESCs) in vivo and prevent or delay the formation of teratomas. ch2448 was raised against hESCs and was previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecd9e6af291b401f2eed087ecbac073a
https://doi.org/10.1002/bit.27135
https://doi.org/10.1002/bit.27135
Autor:
Kylie Su Mei Yong, Simeon Cua, Qingfeng Chen, Leonard Tang Yew Leong, Andre Choo, Heng Liang Tan
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 2
International Journal of Molecular Sciences, Vol 21, Iss 2, p 381 (2020)
Volume 21
Issue 2
International Journal of Molecular Sciences, Vol 21, Iss 2, p 381 (2020)
Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider clinical application, especially in solid tumours. Here, we describe the development of an anti-annexin A2 CAR,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256588581818c2a43a034ea0e3242dca
Autor:
Wey Jia Fong, Vanessa Ding, Andre Choo, Yuansheng Yang, Angela Chin, Heng Liang Tan, Ally Lau, Zhiwei Song, Simeon Cua
Publikováno v:
Oncotarget
Monoclonal antibodies (mAbs) play an increasingly important role in cancer therapy. To address the wide heterogeneity of the disease, the identification of novel antigen targets and the development of mAbs against them are needed. Our lab previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6df97894a1791b2701098b2d9ad5653a
http://europepmc.org/articles/PMC5862572
http://europepmc.org/articles/PMC5862572
Publikováno v:
Cancer Research. 79:1436-1436
Chimeric antigen receptors (CARs) have been a significant focus of cancer therapeutic investigation in recent years, due to the remarkably effective responses observed in hematological cancers. However, the utility of CAR T cells has yet to be fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe6554af32dd72f403aa724a77ccb41a
https://doi.org/10.1158/1538-7445.am2019-1436
https://doi.org/10.1158/1538-7445.am2019-1436
Publikováno v:
International Journal of Molecular Sciences; 1/15/2020, Vol. 21 Issue 2, p1-14, 24p, 1 Diagram, 15 Graphs